Help control your eye pressure and possibly reduce your need for Glaucoma medication with the Hydrus® Microstent.
Location: United States, California, Irvine
Total raised: $120.5M
Investors 8
Funding Rounds 5
| Date | Series | Amount | Investors |
| 10.01.2017 | Series C | $25M | RA Capital... |
| 13.01.2014 | Series B | $46.5M | - |
| 20.08.2013 | Series B | $5M | - |
| 31.01.2013 | Series B | $27M | - |
| 27.06.2011 | - | $17M | - |
Mentions in press and media 13
| Date | Title | Description |
| 15.09.2021 | Ivantis Announces Settlement of Glaukos Patent Litigation | |
| 17.11.2020 | Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines | |
| 10.01.2017 | Term Sheet — Tuesday January 10 | ALL AI EVERYTHING Jocelyn Goldfein has worked on some of Silicon Valley’s most iconic products: She spent seven years as an engineering leader at VMware and four years at Facebook. She even interned at Netscape. In 2014, she started angel i... |
| 10.01.2017 | Ivantis Raises $25M in Series C Funding | Ivantis Inc., an Irvine, CA-based developer of a device designed to lower eye pressure for glaucoma patients, closed a $25m Series C financing. The round was led by new investor RA Capital Management, with participation from new investor Mé... |
| 10.01.2017 | Singapore: EDBI & Vertex Ventures-backed Ivantis closes $25m Series C | Premium Ivantis Inc., developer of the Hydrus Microstent device designed to lower eye pressure for glaucoma patients, has closed a $25 million Series C financing round led by new investor RA Capital Management. The round also included new i... |
| 09.01.2017 | RA Capital Leads $25M Series C for Ivantis | Ivantis Inc., developer of the novel Hydrus™ Microstent device designed to lower eye pressure for glaucoma patients, announced today that it closed a $25 million Series C financing. The round was led by new investor RA Capital Management, a... |
| 09.01.2017 | Ivantis Finds $25M For Microstent Surgery Devices | Irvine-based medical device developer Ivantis, which is developing microstents for minimally invasive glaucoma surgery, has raised $25M in a Series C funding, the company announced today. The funding was led by RA Capital Management, a new ... |
| 13.01.2014 | Ivantis Completes $46.5M Series B Financing | IRVINE, CA, Developer of the novel Hydrus Microstent device designed to lower eye pressure for glaucoma patients, announced today that it secured an additional $14 MM from Vertex Ventures and GBS Ventures in the final close of its Series ... |
| 20.08.2013 | Ivantis Raises $5M in Second Close of Series B Financing | Ivantis, an Irvine, California-based developer of a microstent device designed to lower eye pressure for glaucoma patients, raised $5m in the second close of its Series B financing. This second close was led by EDBI of Singapore. In January... |
| 01.02.2013 | Ivantis reels in $27M Series B round | Wall Street Beat | Ivantis said it raised a $27 million Series B round led by Ascension Health Ventures aimed at funding a quartet of clinical trials for its Hydrus Microstent glaucoma treatment. The Irvine, Calif.-based medical device company said the device... |
Show more